PYXS (Pyxis Oncology) Total Operating Expense: $97.34 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PYXS Pyxis Oncology Inc PYXS
27 GF Score
Price $3.28
! 4 Warning Signs
View Full Analysis

What is Pyxis Oncology Total Operating Expense?

Pyxis Oncology PYXS +2.99% 27 Total Operating Expense is $97.34 Mil as of Mar. 2026. GuruFocus rates PYXS with a GF Score™ of 27/100. The stock has 4 warning signs investors should review.

Pyxis Oncology's Total Operating Expense for the three months ended in Mar. 2026 was $24.36 Mil. Pyxis Oncology's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $97.34 Mil.

Pyxis Oncology Total Operating Expense Related Terms

Pyxis Oncology Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Pyxis Oncology's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pyxis Oncology Total Operating Expense Chart

Pyxis Oncology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 69.72 123.48 82.20 84.17 95.89

Pyxis Oncology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.91 22.57 23.46 26.95 24.36
PYXS
27GF Score
Pyxis Oncology Inc PYXS
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pyxis Oncology Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $97.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $97.34 Mil mean?
Pyxis Oncology (PYXS) has a Total Operating Expense of $97.34 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Pyxis Oncology and its competitors.
Is Pyxis Oncology's Total Operating Expense too high?
Pyxis Oncology's current Total Operating Expense is $97.34 Mil. Overall, Pyxis Oncology has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Pyxis Oncology's Total Operating Expense compare to ORMP and CAMP?
Pyxis Oncology's Total Operating Expense of $97.34 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Pyxis Oncology and its competitors. Pyxis Oncology's current Total Operating Expense is $97.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pyxis Oncology stock overvalued right now?
Pyxis Oncology (PYXS) has a current Total Operating Expense of $97.34 Mil. The current Total Operating Expense is $97.34 Mil. Pyxis Oncology's overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Pyxis Oncology (PYXS), the current Total Operating Expense is $97.34 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pyxis Oncology Business Description

Address 321 Harrison Avenue, Boston, MA, USA, 02118
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
27GF Score

Get the complete analysis for PYXS

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.28
Price